Combination ledipasvir-sofosbuvir for the treatment of chronic hepatitis C virus infection: a review and clinical perspective

Chronic hepatitis C treatment has continued to evolve, and interferon-free, oral treatment with direct-acting antiviral agents is the current standard of care. Recently, a new treatment, which is a combination of two direct-acting antiviral agents, ledipasvir 90 mg (anti-NS5A) and sofosbuvir 400 mg...

Descripción completa

Detalles Bibliográficos
Autores principales: Nkuize, Marcel, Sersté, Thomas, Buset, Michel, Mulkay, Jean-Pierre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4902143/
https://www.ncbi.nlm.nih.gov/pubmed/27350749
http://dx.doi.org/10.2147/TCRM.S77788

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4902143/
https://www.ncbi.nlm.nih.gov/pubmed/27350749
http://dx.doi.org/10.2147/TCRM.S77788

Ejemplares similares